Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

1.

N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior.

Wu L, Ho SV, Wang W, Gao J, Zhang G, Su Z, Hu T.

Int J Pharm. 2013 Sep 10;453(2):533-40. doi: 10.1016/j.ijpharm.2013.06.022. Epub 2013 Jun 21.

PMID:
23796830
[PubMed - indexed for MEDLINE]
2.

A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats.

Cox GN, Rosendahl MS, Chlipala EA, Smith DJ, Carlson SJ, Doherty DH.

Endocrinology. 2007 Apr;148(4):1590-7. Epub 2007 Jan 18.

PMID:
17234711
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Chemical and enzymatic site specific PEGylation of hGH.

da Silva Freitas D, Mero A, Pasut G.

Bioconjug Chem. 2013 Mar 20;24(3):456-63. doi: 10.1021/bc300594y. Epub 2013 Mar 4.

PMID:
23432141
[PubMed - indexed for MEDLINE]
4.

The effect of polyethylene glycol recombinant human growth hormone on growth and glucose metabolism in hypophysectomized rats.

Zhang ZX, Liu YK, Pan H, Pan L, Zhang Q, Su HM, Zhao QL, Li H, He C.

Growth Horm IGF Res. 2012 Feb;22(1):30-5. doi: 10.1016/j.ghir.2011.12.002. Epub 2012 Jan 16.

PMID:
22257554
[PubMed - indexed for MEDLINE]
5.
6.

PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics.

Na DH, Lee KC, DeLuca PP.

Pharm Res. 2005 May;22(5):743-9. Epub 2005 May 17.

PMID:
15906169
[PubMed - indexed for MEDLINE]
8.

Solid-phase N-terminus PEGylation of recombinant human fibroblast growth factor 2 on heparin-sepharose column.

Huang Z, Ye C, Liu Z, Wang X, Chen H, Liu Y, Tang L, Zhao H, Wang J, Feng W, Li X.

Bioconjug Chem. 2012 Apr 18;23(4):740-50. doi: 10.1021/bc200550f. Epub 2012 Apr 2.

PMID:
22433083
[PubMed - indexed for MEDLINE]
9.

Anti-tumor necrosis factor agent PEG-sTNFRI improves the growth hormone/insulin-like growth factor-I system in adjuvant-induced arthritic rats.

Granado M, Priego T, Martín AI, Vara E, López-Calderón A, Angeles Villanúa M.

Eur J Pharmacol. 2006 Apr 24;536(1-2):204-10. Epub 2006 Mar 2.

PMID:
16545800
[PubMed - indexed for MEDLINE]
10.

Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.

Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, Lee KC.

Bioconjug Chem. 2005 Mar-Apr;16(2):377-82.

PMID:
15769092
[PubMed - indexed for MEDLINE]
11.

PEGylation of growth hormone-releasing hormone (GRF) analogues.

Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM.

Adv Drug Deliv Rev. 2003 Sep 26;55(10):1279-91. Review.

PMID:
14499707
[PubMed - indexed for MEDLINE]
12.

Effects of estradiol and exogenous insulin-like growth factor I (IGF-I) on the IGF-I axis during growth hormone inhibition and antagonism.

Wilson ME.

J Clin Endocrinol Metab. 1998 Nov;83(11):4013-21.

PMID:
9814485
[PubMed - indexed for MEDLINE]
13.

The conformation of the poly(ethylene glycol) chain in mono-PEGylated lysozyme and mono-PEGylated human growth hormone.

Pai SS, Hammouda B, Hong K, Pozzo DC, Przybycien TM, Tilton RD.

Bioconjug Chem. 2011 Nov 16;22(11):2317-23. doi: 10.1021/bc2003583. Epub 2011 Oct 6.

PMID:
21950579
[PubMed - indexed for MEDLINE]
14.

Phenyl amide linker improves the pharmacokinetics and pharmacodynamics of N-terminally mono-PEGylated human growth hormone.

Wu L, Ji S, Shen L, Hu T.

Mol Pharm. 2014 Sep 2;11(9):3080-9. doi: 10.1021/mp500266c. Epub 2014 Aug 21.

PMID:
25115329
[PubMed - in process]
15.

Molecular insight into the steric shielding effect of PEG on the conjugated staphylokinase: biochemical characterization and molecular dynamics simulation.

Mu Q, Hu T, Yu J.

PLoS One. 2013 Jul 18;8(7):e68559. doi: 10.1371/journal.pone.0068559. Print 2013.

PMID:
23874671
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Effect of molecular size of PEGylated recombinant human epidermal growth factor on the biological activity and stability in rat wound tissue.

Hee Na D, Seok Youn Y, Bok Lee I, Ji Park E, Jeon Park C, Choon Lee K.

Pharm Dev Technol. 2006;11(4):513-9.

PMID:
17101522
[PubMed - indexed for MEDLINE]
17.

Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.

Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D.

Bioconjug Chem. 2006 May-Jun;17(3):618-30.

PMID:
16704199
[PubMed - indexed for MEDLINE]
18.

Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.

Jo YW, Youn YS, Lee SH, Kim BM, Kang SH, Yoo M, Choi EC, Lee KC.

Int J Pharm. 2006 Feb 17;309(1-2):87-93. Epub 2006 Jan 9.

PMID:
16406701
[PubMed - indexed for MEDLINE]
19.

High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation.

Youn YS, Na DH, Lee KC.

J Control Release. 2007 Feb 26;117(3):371-9. Epub 2006 Nov 23.

PMID:
17207880
[PubMed - indexed for MEDLINE]
20.

Site-specific PEGylation of human thyroid stimulating hormone to prolong duration of action.

Qiu H, Boudanova E, Park A, Bird JJ, Honey DM, Zarazinski C, Greene B, Kingsbury JS, Boucher S, Pollock J, McPherson JM, Pan CQ.

Bioconjug Chem. 2013 Mar 20;24(3):408-18. doi: 10.1021/bc300519h. Epub 2013 Feb 11.

PMID:
23350694
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk